Stay updated on Global Cohort Study: Remibrutinib Clinical Trial
Sign up to get notified when there's something new on the Global Cohort Study: Remibrutinib Clinical Trial page.

Latest updates to the Global Cohort Study: Remibrutinib Clinical Trial page
- Check3 days agoChange DetectedThe page footer’s ClinicalTrials.gov software revision changed from v3.8.0 to v3.8.1; the study record content remains unchanged.SummaryDifference0.1%

- Check10 days agoChange DetectedThe page displays the ClinicalTrials.gov record for Novartis’s remibrutinib managed-access program for adults with chronic spontaneous urticaria, including eligibility criteria, contact information, treatment details, and record dates.SummaryDifference32%

- Check17 days agoChange DetectedThe footer revision identifier changed from v3.7.2 to v3.8.0; the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check31 days agoChange DetectedA site-wide NIH notice about terminology during a website transition appears above the 403 error page, and the site revision advances from v3.7.1 to v3.7.2.SummaryDifference1%

- Check45 days agoChange DetectedThe footer revision identifier was updated from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check59 days agoChange DetectedThe page now shows a 403 Forbidden error instead of the study content, indicating restricted access to the page.SummaryDifference15%

Stay in the know with updates to Global Cohort Study: Remibrutinib Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Global Cohort Study: Remibrutinib Clinical Trial page.